Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...
MIT researchers discovered that the genome’s 3D structure doesn’t vanish during cell division as previously thought. Instead, ...
Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...
Mycobacterium abscessus has emerged as a critical global public health threat, particularly among immunocompromised individuals (van Dorn, 2017). As a rapidly growing nontuberculous mycobacterium (NTM ...
aDepartment of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA bDepartment of Obstetrics, Gynecology, and Women's Health, University of ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Adoptive cell therapy based ...
CRISPR/Cas9 technology has revolutionized genetic and biomedical research in recent years. It enables editing and modulation of gene function with an unparalleled precision and effectiveness. Among ...
The study presents a potentially valuable approach to genetically modify cells to produce extracellular matrices with altered compositions, termed cell-laid, engineered extracellular matrices (eECM).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback